WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

30 November 2017

Transparency Information (ENNL)

24 November 2017

JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix (ENNL)

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
21.67 USD
Change (%):
-2.55 (-10.53%)
BRU
0.93 EUR
Change (%):
-0.11 (-10.51%)